InvestorsHub Logo
icon url

BIOChecker4

01/14/23 1:33 PM

#398251 RE: DFRAI #398243

Some people live in denial despite overwhelming evidence that contradicts their entrenched beliefs. They’re so “invested” in their beliefs that they can’t go back. It takes a mature person to admit that maybe they were wrong, or to at least admit that investors’ concerns need to be addressed.

Missling’s credibility was already in the toilet before CTAD. The CTAD debacle only reinforced existing doubts as to his honesty. If Missling only received the data a day before CTAD, which I doubt, he should have issued a PR saying that and that Anavex was still doing the data analysis and was not ready to present any data at CTAD. I think shareholders would have respected that and the debacle would have been avoided.

Missling has been around the block before with shorts. He should have known he was walking into a trap of his own making. Does he ever learn? Apparently not!
icon url

DFRAI

01/14/23 7:09 PM

#398283 RE: DFRAI #398243

Does anyone have a reasonable answer to below?

Why do we create new scenarios to justify management failures?

PDD full results missing after 18 months
PDD lack of peer reviewed publication
PDD ole is missing in action
ERP biomarkers study for schizo missing
Fragile x - nonstarter after talking for 1 yr
3-71 phase 2 studies missing
Rare disease new - missing in action

Repeated delays, no conclusive data follow up, total disregard for owners of this company - does it not trouble you?

Doesn’t Anavex have enough info to start new trials after 7 years of testing?